AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 in Locally Advanced Pancreatic Cancer.
ByAinvest
Tuesday, Dec 16, 2025 8:52 am ET1min read
Silexion Therapeutics has submitted a Phase 2/3 clinical trial application to Israel for SIL204 in locally advanced pancreatic cancer. The submission follows successful toxicology studies and positive regulatory feedback in Germany, as well as strong preclinical data showing up to 99.7% cancer cell inhibition. Regulatory filings in Germany and the EU are planned for Q1 2026, with U.S. expansion anticipated following the safety run-in. The trial is expected to initiate in Q2 2026.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet